Introduction:
Chugai Pharmaceutical has unveiled its plans to construct a new facility dedicated to the manufacturing of bioactive pharmaceutical ingredients (APIs) as well as an injection building. The two facilities will be loacted in Japan.
Features:
The newly constructed bio-API manufacturing building (UT3) will be specifically designed to facilitate the transition from clinical development to initial commercial production of bio-APIs (biologically active pharmaceutical ingredients).
Its primary purpose is to serve as a dedicated facility for middle to later-stage manufacturing of investigational drugs.
The new manufacturing facilities, UT3 and UTA, will play a significant role in promoting environmental burden reduction. These facilities will incorporate various environmentally friendly features, such as chlorofluorocarbon-free design and energy-saving technologies.
The construction of the new bio-API manufacturing building (UK4) for early-stage clinical development and the existing facilities will create a comprehensive in-house supply foundation. This integrated approach can enhance operational efficiency, shorten lead times, and ensure a reliable and consistent supply of products throughout the development process.
In addition, digital infrastructure will be deployed in both buildings to support the new operations of the production function.
Specifications:
Name Chugai Pharmaceutical
Type New Construction
Budget US$0.35 billion (50 Billion Yen)
